The__O main__O route__O for__O delivering__O impact__O for__O the__O statistical__O QA__O tools__O of__O [1]__B-ORG is__O via__O a__O number__O of__O software__O packages__O [2].__O
These__O include__O affyPLM__O and__O affyQualityMetrics,__O available__O at__O bioconductor.org,__O a__O repository__O for__O free__O open__O source__O bioinformatics__O software,__O started__O in__O 2001__O by__O an__O international__O team__O led__O by__O members__O of__O the__O Fred__B-ORG Hutchinson__I-ORG Cancer__I-ORG Research__I-ORG Center,__I-ORG and__O now__O the__O default__O software__O resource__O for__O the__O bioinformatics__O community.__O
The__O reach__O of__O this__O impact__O is__O considerable.__O
For__O example,__O during__O the__O REF__B-ORG period,__O the__O two__O packages__O have__O been__O downloaded__O from__O Bioconductor__B-LOC over__O 380,000__O times__O [2__O i,__O ii];__O Chipster's__B-MISC server__O in__O Finland__B-LOC (one__O of__O ten__O such__O servers__O worldwide)__O has__O 788__O users__O [2__O iii];__O and__O the__O Genevestigator__B-ORG web__O tool__O which__O uses__O the__O Bioconductor__B-ORG package__O affyQCReport__O (incorporating__O affyPLM)__O for__O the__O QC__O of__O datasets__O is__O used__O for__O [text__O removed__O for__O publication]__O [2__O vi].__O
With__O two__O of__O the__O co-authors__O working__O for__O biotech__O companies__O it__O was__O easy__O to__O establish__O further__O connections__O to__O the__O commercial__O world__O and__O spread__O the__O word__O about__O the__O methodology.__O
Invitations__O to__O conferences__O such__O as__O JSM__O helped__O in__O sharing__O the__O methods,__O both__O with__O other__O statisticians__O and__O with__O users.__O
More__O details__O about__O the__O routes__O to__O impact__O are__O given__O in__O the__O explicit__O examples__O below.__O
(A)__O Process__O improvement__O in__O microarray__O facilities__O and__O standardisation__O of__O data__O quality__O targets__O The__O availability__O of__O QA__B-ORG tools__O [1]__O has__O enabled__O large__O microarray__O facilities__O as__O well__O as__O smaller__O laboratories__O to__O routinely__O monitor__O and__O improve__O their__O processes.__O
This__O enables__O them__O to__O use__O high__O quality__O data__O for__O downstream__O analysis,__O ensuring__O validity__O of__O scientific__O conclusions.__O
Two__O supporting__O letters__O [3,__O 4]__O confirm__O this:__O [3]__O CEO__O of__O Spheromics__B-ORG (formerly__I-ORG at__I-ORG Novartis__I-ORG and__O the__O Australian__B-MISC Genome__I-MISC Research__I-MISC Facility):__I-MISC "Quality__O assessment__O and__O control__O for__O microarray__O data__O is__O an__O area__O where__O existing__O quality__O control__O methodology__O was__O not__O sufficiently__O developed__O [...].__O
The__O methodology__O [from__B-ORG [1]]__I-ORG has__O been__O helpful__O to__O me__O for__O both__O detecting__O outlier__O arrays__O and__O revealing__O systematics__O errors__O in__O the__O process.__O
[...]__O I__O have__O been__O using__O the__O tools__O proposed__O and__O the__O guidance__O about__O their__O interpretation,__O in__O particularly__O the__O NUSE__B-ORG distributions.__O
They__O would__O highlight,__O at__O a__O glance,__O differences__O of__O chip__O quality__O caused__O by__O batch__O effects."__O
[4]__O Senior__O Bioinformatics__O Officer__O at__O ICR__O (Institute__O of__O Cancer__B-LOC Research):__I-LOC "We__O use__O quality__O assessment__O based__O on__O statistics__O methods__O developed__O by__O [1]__O implemented__O in__O R-packages.__B-LOC
Quality__O assessment__O has__O been__O helpful__O to__O us__O in__O determining__O outlier__O arrays__O and__O detecting__O artefacts__O in__O the__O data.__O
This__O makes__O sure__O our__O dataset__O is__O not__O distorted__O by__O poor__O quality__O microarrays."__O
The__O QA__O methods__O from__O [1]__B-ORG have__O contributed__O to__O changing__O attitudes__O in__O the__O genomics__O community,__O both__O in__O academia__O and__O beyond,__O towards__O giving__O higher__O priority__O to__O routine__O checking__O of__O data__O quality__O and__O to__O understanding__O of__O technically__O caused__O variation__O before__O drawing__O scientific__O conclusions.__O
For__O example:__O &#8212;__O The__O quality__O landscapes__O feature__O provide__O a__O visual__O presentation__O of__O quality__O defects,__O thereby__O allowing__O scientists__O to__O identify,__O in__O the__O measurement__O process,__O specific__O causes__O of__O poor__O quality.__O
The__O popularity__O of__O [5]__O (e.g.,__O 10715__O visits__O in__O the__O 12__O months__O preceding__O February__O 2013)__O confirms__O the__O usefulness__O of__O this__O approach.__O
&#8212;__O Making__O use__O of__O the__O QA__B-ORG tools__O for__O microarray__O data__O has__O become__O a__O routine__O step__O in__O scientific__O studies__O to__O ensure__O the__O reproducibility__O of__O research__O findings;__O see__O e.g.__O
[6]__O for__O one__O of__O many__O examples.__O
Many__O authors__O cite__O the__O software__O or__O names__O of__O the__O QA__O tools__O (RLE,__B-ORG NUSE)__I-ORG rather__O than__O the__O publication__O [1].__O
The__O methods__O [1]__B-ORG have__O played__O important__O roles__O in__O setting__O professional__O standards__O for__O microarray__O data__O quality,__O as__O illustrated__O by__O an__O international__O initiative__O led__O by__O the__O US__B-ORG Food__I-ORG and__I-ORG Drug__I-ORG Administration__I-ORG (FDA).__O
The__O Microarray__B-ORG Quality__I-ORG Control__I-ORG (MAQC)__I-ORG project__O aims__O at__O establishing__O standards__O to__O ensure__O successful__O and__O reliable__O use__O in__O clinical__O practice__O and__O regulatory__O decision-making.__O
Phase__O II__O aimed__O to__O assess__O and__O establish__O "best__O practices"__O for__O development__O and__O validation__O of__O predictive__O models__O for__O personalised__O medicine.__O
CEO__O of__O Spheromics,__B-LOC who__O was__O involved__O in__O the__O project,__O states__O in__O his__O letter__O [3]__O "In__O Phase__O II__O of__O that__O project,__O I__O have__O made__O frequent__O use__O of__O the__O assessment__O methods__O from__O your__O paper."__O
(B)__O Individualisation__O of__O treatment__O decisions__O In__O the__O last__O decade,__O many__O biotech__O companies__O have__O been__O pushing__O for__O the__O development__O of__O diagnostic__O and__O prognostic__O tools__O to__O support__O the__O optimisation__O of__O treatment__O choices.__O
For__O example,__O individualised__O recurrence__O estimates__O help__O decide__O whether__O or__O not__O a__O patient__O would__O benefit__O from__O adjuvant__O chemotherapy.__O
Clearly__O the__O need__O for__O high__O quality__O standards__O becomes__O increasingly__O important__O the__O closer__O the__O use__O of__O a__O tool__O gets__O to__O a__O clinical__O setting.__O
The__O QA__B-MISC methods__O developed__O in__O [1]__O are__O being__O used__O in__O the__O research__O units__O of__O companies__O developing__O tools__O for__O personalised__O medicine.__O
We__O demonstrate__O this__O in__O detail__O for__O Veracyte,__O a__O molecular__O diagnostics__O company__O and__O a__O pioneer__O in__O the__O emerging__O field__O of__O molecular__O cytology.__O
Veracyte__O has__O developed__O a__O gene__O expression__O based__O test__O called__O Afirma__B-PER that__O is__O expected__O to__O reduce__O massively__O the__O number__O of__O surgeries__O with__O their__O attendant__O morbidity__O (life-long__O follow-up__O treatments)__O in__O initially__O suspected__O thyroid__O cancer__O due__O to__O the__O occurrence__O of__O fairly__O common__O thyroid__O nodules.__O
A__O recent__O economic__O impact__O study__O in__O the__O Journal__B-ORG of__I-ORG Clinical__I-ORG Endocrinology__I-ORG and__I-ORG Metabolism__I-ORG concluded__O that__O routine__O use__O of__O Afirma__B-LOC in__O the__O USA__B-LOC would__O result__O in__O 74%__O fewer__O surgeries__O in__O patients__O with__O benign__O tumours,__O that__O is,__O tens__O of__O thousands__O of__O avoidable__O surgeries__O each__O year__O corresponding__O to__O about__O $122__O million__O medical__O savings__O [7].__O
The__O traditional__O diagnosis__O of__O thyroid__O cancer__O produces__O up__O to__O 30%__O inconclusive__O cases__O which__O typically__O result__O in__O surgery,__O of__O which__O 70%-80%__O of__O patients__O turn__O out__O to__O have__O benign__O tumours.__O
Afirma__O succeeds__O in__O avoiding__O the__O need__O for__O surgery__O in__O about__O half__O of__O such__O cases,__O resulting__O in__O expected__O health__O care__O cost__O savings__O of__O $3000__O per__O patient__O as__O well__O as__O improving__O patient__O health__O outcomes.__O
Afirma__O has__O been__O developed__O and__O clinically__O validated__O as__O published__O in__O 2012__O in__O high-profile__O journals__O such__O as__O the__O New__B-ORG England__I-ORG Journal__I-ORG of__O Medicine__B-LOC (NEJM)__I-LOC [8].__O
A__O crucial__O step__O for__O the__O commercial__O success__O of__O Afirma__B-ORG is__O to__O obtain__O medical__O insurance__O cover,__O e.g.,__O it__O was__O approved__O by__O Medicare__B-MISC in__O 2012.__O
For__O this,__O FDA__B-ORG software__O validation__O is__O key,__O a__O step__O that__O takes__O six__O months__O and__O about__O $300,000__O and__O after__O which__O the__O algorithm__O is__O locked.__O
To__O ensure__O their__O success__O in__O winning__O over__O the__O clinicians,__O Veracyte__O needed__O the__O negative__O predictive__O value__O of__O their__O tool__O to__O be__O above__O 94%,__O which__O required__O the__O highest__O possible__O quality__O standards.__O
Veracyte's__O Chief__O Scientific__B-PER Officer__I-PER states__O in__O her__O supporting__O letter__O [9]:__O "A__O recent__O study__O found__O that__O the__O Afirma__B-ORG Gene__I-ORG Expression__I-ORG Classifier__I-ORG demonstrated__O strong__O accuracy,__O reliability__O and__O reproducibility__O under__O a__O range__O of__O conditions__O and__O variables.__O
This__O includes__O maintenance__O of__O sample__O stability,__O analytic__O sensitivity__O and__O analytical__O specificity__O [...]__O A__O key__O step__O to__O these__O achievements__O is__O data__O quality__O assessment__O and__O control.__O
We__O have__O been__O using__O quality__O assessment__O methods__O such__O as__O summaries__O of__O RLE__B-ORG distributions__O from__O your__O publication__O to__O shed__O light__O on__O the__O sources__O of__O variation__O in__O our__O custom-made__O gene__O expression__O microarrays.__O
[They]__O have__O been__O serving__O us__O for__O detecting__O outliers__O as__O well__O as__O for__O revealing__O and__O removing__O artefacts__O and__O batch__O effects__O arising__O from__O inconsistencies__O in__O operator,__O protocol__O or__O sample__O condition."__O
Several__O media__O stories__O from__O 2012__O onwards__O highlight__O how__O particular__O patients,__O after__O having__O taken__O the__O Afirma__B-LOC test,__O have__O avoided__O surgery__O with__O long__O term__O health__O savings__O and__O improved__O patient__O welfare__O [10].__O
